Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: A consensus report

European Journal of Endocrinology

Volumn 153, Issue 5, 2005, Pages 651-659

  Pacini, Furio ⁿ   Schlumberger, Martin ^a   Harmer, Clive ^b   Berg, Gertrud G ^c   Cohen, Ohad ^d   Duntas, Leonidas ^e   Jamar, François ^f   Jarzab, Barbara ^g   Limbert, Eduard ^h   Lind, Peter ⁱ   Reiners, Cristoph ^j   Franco, Franco Sanchez ^k   Smit, Johannes ^l   Wiersinga, Wilmar ^m  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d SHEBA MEDICAL CENTER   (Israel)

^e Evgenidion Hospital   (Greece)

^f UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^g INSTITUTE OF ONCOLOGY   (Poland)

^h Portuguese Cancer Institute   (Portugal)

ⁱ GENERAL HOSPITAL KLAGENFURT   (Austria)

^j UNIVERSITY OF WÜRZBURG   (Germany)

^k HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^l LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^m ACADEMIC MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF SIENA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IODINE 131; LIOTHYRONINE; RECOMBINANT THYROTROPIN; THYROXINE;

AMENORRHEA; ARTICLE; CANCER; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG USE; DRY EYE; FOLLOW UP; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; LACRIMAL DUCT OCCLUSION; LEUKEMIA; LYMPH NODE DISSECTION; META ANALYSIS; METASTASIS; METHODOLOGY; NAUSEA; OLIGOSPERMIA; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RECURRENCE RISK; RECURRENT CANCER; SIALOADENITIS; SPONTANEOUS ABORTION; STOMACH PAIN; SYSTEMATIC REVIEW; TASTE DISORDER; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; THYROIDECTOMY; THYROIDITIS; TREATMENT INDICATION; TREATMENT OUTCOME; XEROSTOMIA;

CARCINOMA, PAPILLARY, FOLLICULAR; CONSENSUS; HUMANS; IODINE RADIOISOTOPES; NEOPLASM, RESIDUAL; POSTOPERATIVE CARE; RADIOTHERAPY, ADJUVANT; THYROID NEOPLASMS;

EID: 27944491523     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.02014     Document Type: Article

References (52)

1. Maxon HR & Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinology Metabolism Clinics of North America 1990 19 685-718.
2. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G & Gerstein HC. A systemic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2004 89 3668-3676.
3. Eustatia-Rutten CFA, Smit JWA, Romijn JA, van der Kleij-Corssmit EPM, Pereira AM, Stokkel MP & Kievit J. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clinical Endocrinology 2004 61 61-74.
4. American Joint Committee on Cancer, Thyroid. In AJCC Cancer Staging Handbook, edn 6, Chapter 8, pp 89-98. Eds. FL Greene, DL Page, ID Fleming, AG Fritz, CM Balch, DG Haller & M Morrow, New York: Springer, 2002.
5. Baudin E, Travagli JP, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, Cailleux AF, Lumbroso ID, Parmentier C & Schlumberger M. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998 83 553-559.
6. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA & Goellner JR. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World Journal of Surgery 2002 26 879-885.
7. Haugen BR. Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. Journal of Clinical Endocrinology and Metabolism 2004 89 3665-3667.
8. Verburg FA, de Keizer B, Lips CJ, Zelissen PM & Klerk JM. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. European Journal of Endocrinology 2005 152 33-37.
9. Mazzaferri EL & Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism 2001 86 1447-1463.
10. Wartofsky L, Sherman SI, Gopal J, Schlumberger M & Hay ID. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. Journal of Clinical Endocrinology and Metabolism 1998 83 4195-4203.
11. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos T, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S & Maxon HR. Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. Annals of Internal Medicine 1998 129 622-627.
12. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK & Sutcliffe SB. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 1998 82 375-388.
13. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, Caillou B, Travagli JP & Parmentier C. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985 55 794-804.
14. Schlumberger M. Papillary and follicular thyroid carcinoma. New England Journal of Medicine 1998 338 297-306.
15. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D & Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003 97 90-96.
16. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L & Pinchera A. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2003 88 3668-3673.
17. Torlontano, M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G, D'Azzo G, Meringolo D, Ferretti E, Sacco R, Arturi F & Filetti S. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. Journal of Clinical Endocrinology and Metabolism 2004 89 3402-3407.
18. Cailleux AF, Baudin E, Travagli JP, Ricard M & Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid carcinoma? Journal of Clinical Endocrinology and Metabolism 2000 85 175-178.
19. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L & Pinchera A. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Annals of Internal Medicine 2003 139 346-351.
20. 131I therapy for elevated thyroglobulin levels. Thyroid 1997 7 273-276.
21. 131I activities versus untreated patients. Journal of Clinical Endocrinology and Metabolism 2001 86 4092-4097.
22. 131I ablation therapy in patients with differentiated thyroid cancer. Journal of Nuclear Medicine 2004 45 988-994.
23. 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2005 90 1440-1445.
24. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Ceccarelli C, Taddei D, Elisei R, Capezzone M & Pinchera A. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2001 86 5686-5690.
25. Park HM, Perkins OW, Edmondson JW, Schnute RB & Manatunga A. Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131. Thyroid 1994 4 49-54.
26. Luster M, Sherman SI, Skarulis MC, Reynolds JR, Lassmann M, Hänscheid H & Reiners C. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging 2003 30 1371-1377.
27. Luster M, Felbinger R, Dietlein M & Reiners C. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a 130-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison with recombinant thyrotropin administration. Thyroid 2005 (In Press).
28. Pacini F, Ladenson PW Schlumberger M, Driedger A, Kloos RT, Sherman S, Corone C, Haugen B & Reiners C. Praparation with thyrotropin alfa is equivalent to thyroid hormone withdrawal as preparation for thyroid remnant ablation in differentiated thyroid carcinoma. Turkish Journal of Endocrinology Metabolism 2004 8 (Suppl 1) 21.
29. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R & Tuttle RM. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. Journal of Nuclear Medicine 2002 43 1482-1488.
30. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M & Mariani G. Radioiodine treatment with 30 mCi after recombinant human TSH stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. Journal of Clinical Endocrinology and Metabolism 2003 88 4110-4115.
31. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. Journal of Clinical Endocrinology and Metabolism 2002 87 4063-4068.
32. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP & Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. Journal of Clinical Endocrinology and Metabolism 2003 88 1107-1111.
33. 131I for the treatment of differentiated thyroid carcinoma. Journal of Nuclear Medicine 2005 46 28S-37S.
34. 131I for remnant ablation in patients with differentiated thyroid carcinoma. Cancer 1996 77 2574-2580.
35. Bal CS, Kumar A & Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. Journal of Clinical Endocrinology and Metabolism 2004 89 1666-1673.
36. Creutzig H. High or low dose radioiodine ablation of thyroid remnants? European Journal of Nuclear Medicine 1987 12 500-502.
37. Johansen K, Woodhouse NJ & Odugbesan O. Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. Journal of Nuclear Medicine 1991 32 252-254.
38. 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. Nuclear Medicine Communications 2004 25 1077-1081.
39. 131 for post operative remnant ablation in differentiated thyroid cancer. World Journal of Nuclear Medicine 2004 3 (Suppl 1) S36.
40. Randolph GW & Daniels GH. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular cancer of the thyroid. Thyroid 2002 12 989-996.
41. 131I ablation as an alternative to completion /total thyroidectomy in the treatment of well-differentiated thyroid cancer. Surgery 2004 136 1275-1280.
42. Schlumberger M, Pacini F, Wiersinga WM, Toft A, Smit JWA, Franco FS, Lind P, Limbert E, Jarzab B, Jamar F, Duntas L, Cohen O & Berg G. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. European Journal of Endocrinology 2004 151 539-548.
43. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Franco FS, Toft A & Wiersinga WM. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. European Journal of Endocrinology 2004 50 105-112.
44. Mandel SJ & Mandel L. Radioactive iodine and the salivary glands. Thyroid 2003 13 265-271.
45. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y & Noguchi S. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? Journal of Nuclear Medicine 2005 46 261-266.
46. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA & Burns JA. Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 2002 87 5817-5820.
47. Solans R, Bosch JA, Galofré P, Porta F, Rosello J, Selva-O'Callagan A & Vilardell M. Salivary and lachrymal gland dysfunction (Sicca syndrome) after radioiodine therapy. Journal of Nuclear Medicine 2001 42 738-743.
48. 131-I therapy for ablation of postsurgical thyroid remnants in patients with differentiated thyroid cancer. Journal of Nuclear Medicine 1999 40 1716-1721.
49. Pacini F, Gasperi M, Fugazzola L, Ceccarelli C, Lippi F, Centoni R, Martino E & Pinchera A. Testicular function in patients with differentiated thyroid carcinoma treated with radioiodine. Journal of Nuclear Medicine 1994 35 1418-1422.
50. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. Journal of Clinical Endocrinology and Metabolism 2001 86 3512-3515.
51. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A & Parmentier C. Exposure to radioiodine (I-131) for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. Journal of Nuclear Medicine 1996 37 606-612.
52. Rubino C, De Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C & Schlumberger M. Second primary malignancies in thyroid cancer patients. British Journal of Cancer 2003 89 1638-1644.